These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 29697929

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.
    Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, Marberger M.
    Urology; 1999 Sep; 54(3):517-22. PubMed ID: 10475364
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone.
    Liu B, Pan TJ.
    Urologia; 2014 Sep; 81(3):173-6. PubMed ID: 24557815
    [Abstract] [Full Text] [Related]

  • 25. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml-1.
    Wang C, Wang YY, Wang SY, Ding JX, Ding M, Ruan Y, Wang XH, Jing YF, Han BM, Xia SJ, Jiang CY, Zhao FJ.
    Asian J Androl; 2021 Sep; 23(4):415-420. PubMed ID: 33473011
    [Abstract] [Full Text] [Related]

  • 26. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels.
    Furuya Y, Ohta S, Sato N, Kotake T, Sugano I, Nagao K, Masai M.
    Anticancer Res; 2001 Sep; 21(2B):1317-20. PubMed ID: 11396206
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Evaluation of prostate specific antigen (PSA) adjusted to transition zone in prostatic cancer detection].
    Jara Rascón J, Subirá Rios D, Lledó Garcia E, Martínez Salamanca JI, Moncada Iribarren I, Hernández Fernández C.
    Actas Urol Esp; 2005 May; 29(5):485-92. PubMed ID: 16013794
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D, Kamil ST, Pakasi LS.
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [Abstract] [Full Text] [Related]

  • 31. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B, Zlotta AR, Remzi M, Ghawidel K, Bursa B, Hruby S, Wolfram R, Schulman CC, Marberger M.
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [Abstract] [Full Text] [Related]

  • 32. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y.
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [Abstract] [Full Text] [Related]

  • 33. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA, Oguz O, Olgun A, Seçkin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T.
    Ann Clin Lab Sci; 2002 Jun; 32(1):22-30. PubMed ID: 11848613
    [Abstract] [Full Text] [Related]

  • 34. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T, Kinjo M, Watanabe K, Noda H, Kato M, Miyata A, Murata A, Yoshii M, Nutahara K, Higashihara E.
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [Abstract] [Full Text] [Related]

  • 35. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K.
    Cancer; 2005 Sep 01; 104(5):993-1003. PubMed ID: 16007682
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH.
    Urology; 1995 Dec 01; 46(6):779-84. PubMed ID: 7502415
    [Abstract] [Full Text] [Related]

  • 38. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction.
    Zlotta AR, Djavan B, Marberger M, Schulman CC.
    J Urol; 1997 Apr 01; 157(4):1315-21. PubMed ID: 9120930
    [Abstract] [Full Text] [Related]

  • 39. [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen].
    Schmid HP, Ravery V, Toublanc M, Boccon-Gibod L.
    Schweiz Med Wochenschr; 1996 Sep 07; 126(36):1530-5. PubMed ID: 8927956
    [Abstract] [Full Text] [Related]

  • 40. [Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy].
    Rodríguez-Patrón Rodríguez R, Mayayo Dehesa T, González Galán A, Zuccarino AL, García González R, Cuesta Roca C.
    Arch Esp Urol; 2002 Dec 07; 55(10):225-34. PubMed ID: 12611220
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.